HIF Enhancer於慢性腎病未透析病人之使用

HIF Enhancer for Anemia in Patients with Kidney Disease Not Receiving Dialysis

洪維澤(Wei-Tse Hong) ； 楊韻紅(Yun-Hong Yang)

《腎臟與透析》 35卷1期 (2023/03) Pp. 26-29

https://doi.org/10.6340/KD.202303_35(1).0004

摘要

貧血為慢性腎臟病（chronic kidney disease）常見的併發症，主要受腎臟紅血球生成素分泌不足影響。人體組織中如有發生缺氧，脯氨酸羥化酶（prolyl hydroxylase）會受到抑制，進而使缺氧誘導因子（hypoxia-inducible factor, HIF）的抑制停止，導致HIF的活性上升，使紅血球生成素（erythropoietin, EPO）的製造增加。HIF enhancer在此扮演著HIF脯氨酸羥化酶抑制劑（prolyl hydroxylase inhibitor）的角色，可穩定缺氧誘導因子，進而刺激內源性紅血球生成素的產生。

關鍵字

貧血 ； 脯氨酸羥化酶抑制劑 ； 紅血球生成素

並列摘要

Anemia is a common complication of chronic kidney disease, primarily due to insufficient secretion of erythropoietin by the kidney. In hypoxic condition, prolyl hydroxylase activity is inhibited, thereby stopping the inhibition of hypoxia-inducible factor (HIF), resulting in an increase in the activity of HIF. HIF enhancer plays a role as a prolyl hydroxylase inhibitor and then stabilizes HIF, leading to the stimulation of the production of endogenous erythropoietin.

並列關鍵字

anemia ； HIF ； EPO